What is Zacks Research’s Estimate for MetaVia Q1 Earnings?

MetaVia Inc. (NASDAQ:MTVA) – Equities researchers at Zacks Research issued their Q1 2026 earnings estimates for MetaVia in a research report issued to clients and investors on Tuesday, March 31st. Zacks Research analyst D. Bautz forecasts that the company will earn ($0.74) per share for the quarter. The consensus estimate for MetaVia’s current full-year earnings is ($3.90) per share. Zacks Research also issued estimates for MetaVia’s Q2 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($1.53) EPS and FY2028 earnings at ($1.43) EPS.

Other research analysts have also issued reports about the company. Wall Street Zen raised MetaVia from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. HC Wainwright lowered their target price on MetaVia from $40.00 to $20.00 and set a “buy” rating for the company in a report on Friday, March 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of MetaVia in a report on Monday, December 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $26.50.

MetaVia Trading Up 4.2%

Shares of MTVA opened at $1.25 on Thursday. The firm’s fifty day simple moving average is $1.70 and its two-hundred day simple moving average is $6.66. MetaVia has a 12 month low of $1.17 and a 12 month high of $23.10. The stock has a market capitalization of $2.75 million, a P/E ratio of -0.15 and a beta of 0.35.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC acquired a new stake in MetaVia Inc. (NASDAQ:MTVA) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned 0.14% of MetaVia as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 1.37% of the company’s stock.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.